FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MA6KEU9

Market Closed - Börse Stuttgart 20:42:45 27/06/2024 BST
3.35 EUR -4.01% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month+94.97%
1 month+102.91%
Date Price Change
27/06/24 3.35 -4.01%
26/06/24 3.49 +3.56%
25/06/24 3.37 +19.93%
24/06/24 2.81 +19.57%
21/06/24 2.35 +6.33%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 08:42 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MA6KEU
ISINDE000MA6KEU9
Date issued 10/05/2021
Strike 31.81 $
Maturity Unlimited
Parity 4.3 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.68
Lowest since issue 1.55
Spread 0.02
Spread %0.59%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
47.23 USD
Average target price
58.38 USD
Spread / Average Target
+23.62%
Consensus